Biolidics Ltd. (8YY) AI Stock Analysis

• Market Cap: S$39.87M
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.00
• Shares Outstanding: 1,733,441,800
• 10 Day Avg. Volume: 213,000
• 30 Day Avg. Volume: 1,640,769
• PEG Ratio: 0.50
• Price to Book (P/B): 16.43
• Price to Sales (P/S): 36.30
• P/FCF Ratio: -12.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

Biolidics Ltd. shows strong revenue growth but struggles with profitability and operational efficiency, significantly impacting its financial performance score. Technical indicators suggest limited momentum, and the valuation is unattractive due to negative earnings and no dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Biolidics Ltd. Business Overview & Revenue Model

Company Description

Biolidics Ltd. (8YY) is a biotechnology company based in Singapore that specializes in the development and commercialization of innovative diagnostic solutions for the healthcare sector. The company focuses on providing advanced medical technologies, particularly in the areas of cancer diagnostics and the detection of infectious diseases. Biolidics' core products include its proprietary cancer detection assays and a range of diagnostic kits aimed at improving patient outcomes and streamlining healthcare processes.

How the Company Makes Money

Biolidics generates revenue through multiple streams, primarily by selling its diagnostic products and services to hospitals, clinics, and laboratories. The company earns income from the direct sale of its proprietary cancer detection assays and related diagnostic kits, which are designed to improve the accuracy and efficiency of disease detection. Additionally, Biolidics may also engage in strategic partnerships with healthcare organizations, research institutions, and pharmaceutical companies to co-develop new diagnostic technologies, providing opportunities for licensing fees and collaborative research funding. The company may further enhance its revenue through government grants and subsidies aimed at supporting healthcare innovation, as well as potential international expansion into new markets where its products can address unmet medical needs.

Biolidics Ltd. Financial Statement Overview

Summary

Biolidics Ltd. is experiencing significant revenue growth, but profitability remains a major concern with persistent losses. The balance sheet shows a moderate level of leverage, but the negative return on equity highlights inefficiencies in generating shareholder value. Cash flow improvements are noted, yet operational cash generation is still inadequate. The company needs to focus on improving profitability and operational efficiency to enhance its financial stability.

Income Statement

Biolidics Ltd. has shown a significant revenue growth rate of 380.98% in the latest year, indicating a strong recovery in sales. However, the company continues to face challenges with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from previous years, reflecting potential cost management issues.

Balance Sheet

The company's debt-to-equity ratio is slightly above 1, indicating a balanced leverage position. However, the negative return on equity suggests that the company is not generating sufficient returns for its shareholders. The equity ratio is not provided, but the overall financial health appears to be strained by consistent losses.

Cash Flow

Biolidics Ltd. has shown a positive free cash flow growth rate, which is a positive indicator for liquidity. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is below 1, indicating that the company is not generating enough cash from its operations to cover its net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.48M	784.00K	277.00K	2.49M	2.31M	9.27M
Gross Profit	653.00K	187.00K	146.00K	1.16M	483.00K	3.80M
EBITDA	-2.58M	-3.03M	-1.16M	-8.50M	-4.58M	-3.52M
Net Income	-2.67M	-3.43M	-2.49M	-9.37M	-5.98M	-4.65M
Balance Sheet
Total Assets	4.80M	4.67M	682.00K	6.09M	11.42M	18.76M
Cash, Cash Equivalents and Short-Term Investments	300.00K	295.00K	183.00K	5.03M	3.96M	10.67M
Total Debt	2.52M	1.75M	2.02M	3.01M	4.25M	5.28M
Total Liabilities	3.69M	2.94M	2.67M	7.78M	9.09M	10.48M
Stockholders Equity	1.11M	1.73M	-1.99M	-1.69M	2.33M	8.27M
Cash Flow
Free Cash Flow	-2.69M	-2.32M	-1.97M	-3.16M	-5.20M	-2.76M
Operating Cash Flow	-2.68M	-2.31M	-1.97M	-3.06M	-4.64M	-2.43M
Investing Cash Flow	-5.00K	-5.00K	-2.69M	5.00K	-860.00K	-539.43K
Financing Cash Flow	2.83M	2.36M	-200.00K	4.18M	-1.15M	7.50M

Biolidics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Negative. The current price of 0.02 is equal to the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of -88.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8YY.

Biolidics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1B1	―	S$52.29M	6.19	47.36%	―	1.58%	115.29%
569	―	S$48.55M	―	-3.23%	―	13.07%	-70.37%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
42C	―	S$104.88M	―	-431.07%	―	30.34%	17.14%
8YY	―	S$39.87M	―	―	―	―	―

Biolidics Ltd. Corporate Events

Embracing Future Holdings Expands Share Capital with New Issuance

Embracing Future Holdings Limited has completed the allotment and issuance of new ordinary shares, increasing its total issued and paid-up share capital from 1,690,758,836 to 1,733,441,815 shares. This issuance, which includes various categories of shares such as Yuan Sign-On Shares and ECA Shares, is expected to be listed on the Catalist of the SGX-ST. The completion of this process marks a significant step in the company’s capital expansion strategy, potentially impacting its market positioning and offering new opportunities for stakeholders.

Embracing Future Holdings Secures SGX Approval for New Share Listings

Embracing Future Holdings Limited has received approval from the Singapore Exchange Securities Trading Limited for the listing and quotation of various new shares, including Yuan Sign-On Shares and ECA Shares, on the Catalist board. This development is part of the company’s strategic efforts to enhance its capital structure and market presence, potentially impacting its operational capabilities and stakeholder interests.